The National Healthcare Security Administration (NHSA) has unveiled the adjustment plan for the National Reimbursement Drug List (NRDL) for the current year and is soliciting public feedback until June 19, 2024. The NHSA has outlined the criteria for drug inclusion, which aligns with previous years’ requirements.<\/p>\n\n\n\n
Eligibility for inclusion on the NRDL is granted to drugs that meet any of the following criteria:
\u2460 New generic drugs approved for marketing by the National Medical Products Administration (NMPA) between January 1, 2019, and June 30, 2024.
\u2461 Drugs with significant changes in indications or functional indications approved by the NMPA during the same period.
\u2462 Drugs listed in the National Essential Drug List (2018 Edition).
\u2463 Drugs included in the list of generic drugs or pediatric drugs encouraged for development and approved for marketing by the NMPA before June 30, 2024.
\u2464 Rare disease drugs approved for marketing by the NMPA before June 30, 2024.<\/p>\n\n\n\n
Furthermore, the NHSA has clarified the conditions under which drugs may be removed from the NRDL:
\u2460 Drugs that have not been supplied to designated medical institutions under medical insurance in the past three years.
\u2461 Negotiated drugs that have not been guaranteed market supply as of June 30, 2024.
\u2462 Drugs that comply with the provisions of Article 9 and Article 10 of the Interim Measures for the Administration of Medication in Basic Medical Insurance (BMI), which include drugs that have been revoked or cancelled, drugs with risks greater than benefits, drugs with unreasonable and high prices, and drugs that do not meet safety, effectiveness, and budget requirements.<\/p>\n\n\n\n